vimarsana.com

Page 8 - மருத்துவ புற்றுநோய் ஆராய்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Imugene Ltd advances clinical trial activity over busy June quarter

Imugene Ltd advances clinical trial activity over busy June quarter
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

Medical Research News - Page 5514

22 Mar 2004 Adrian Bird and Skirmantas Kriaucionis of the University of Edinburgh have discovered a novel form of the protein MeCP2. This alternate form, coined MeCP2 alpha, differs from the original only in the first 19 amino acids. Interestingly, Adrian Bird, Director of the Welcome Trust Centre for Cell Biology at Edinburgh University, found that MeCP2 alpha, is ten times more prevalent not only in the brain but also in other tissues. These findings are currently reported online in Nucleic Acids Research. Similar findings were reported yesterday in Nature Genetics online by Berge Minassian, a neurologist and scientist at Toronto s Hospital for Sick Children.

Researchers use appendiceal cancer organoids to study personalized immunotherapy response

Researchers use appendiceal cancer organoids to study personalized immunotherapy response Wake Forest researchers and clinicians are using patient-specific tumor organoid models as a preclinical companion platform to better evaluate immunotherapy treatment for appendiceal cancer, one of the rarest cancers affecting only 1 in 100,000 people. Immunotherapies, also known as biologic therapies, activate the body s own immune system to control, and eliminate cancer. Appendiceal cancer is historically resistant to systemic chemotherapy, and the effect of immunotherapy is essentially unknown because clinical trials are difficult to perform due to lack of adequate patient numbers, resulting in a lack of data and limited research models.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.